Efficacy and safety of alirocumab in people with prediabetes vs those with normoglycaemia at baseline: a pooled analysis of 10 phase III ODYSSEY clinical trials

Aim To assess the lipid‐lowering efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in people with hypercholesterolaemia and prediabetes at baseline vs people with normoglycaemia at baseline in a pooled analysis of 10 ODYSSEY phase III trials. Metho...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetic medicine 2018-01, Vol.35 (1), p.121-130
Hauptverfasser:	Leiter, L. A., Müller‐Wieland, D., Baccara‐Dinet, M. T., Letierce, A., Samuel, R., Cariou, B.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Humanized Anticholesteremic Agents - therapeutic use Blood glucose Blood Glucose - metabolism Case-Control Studies Cholesterol Cholesterol, LDL - metabolism Clinical trials Clinical Trials, Phase III as Topic Diabetes Diabetes mellitus Double-Blind Method Fasting Female Glucose Glycated Hemoglobin - metabolism Homeostasis Humans Hypercholesterolemia - complications Hypercholesterolemia - drug therapy Hypercholesterolemia - metabolism Kexin Laboratory testing Low density lipoprotein Male Middle Aged Monoclonal antibodies Motivation Prediabetic State - complications Prediabetic State - metabolism Proprotein convertases Randomized Controlled Trials as Topic Research: Treatment Safety Statins Subtilisin Treatment Outcome Triglycerides Triglycerides - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!